When John and Pam Witt got the news that their son Zach's lymphoma had relapsed, they felt helpless and scared. But doctors at The Children's Hospital of Philadelphia were optimistic about an experimental treatment that they believed could save the 5-year-old's life. Zach's lymphoma is characterized by changes in the ALK gene. These changes in the make the lymphoma cells grow out of control. An ALK-inhibiting drug called crizotinib was developed to target the gene directly, which turns off that driving signal.
Related Centers and Programs: